|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 6,204,257
What does U.S. Patent 6,204,257 cover?
U.S. Patent 6,204,257 primarily pertains to compositions and methods related to the regulation of specific biological pathways, with a focus on inhibitors targeting phosphodiesterase (PDE) enzymes. It claims novel compounds, particular formulations, and therapeutic applications primarily involving PDE inhibitors for various disease treatments.
Patent Scope Summary
- Filed: November 3, 1998
- Issued: March 20, 2001
- Assignee: Pfizer Inc.
- Priority: Claims priority to provisional applications filed in 1997 and 1998
- Domains: Pharmacology, medicinal chemistry, therapeutic methods, and compound formulation
What are the key claims?
Core Claims
- Compound claims: The patent claims specific chemical compounds characterized by a heterocyclic core structure with attached substituents. These compounds demonstrate PDE inhibitory activity.
- Method claims: Methods of inhibiting PDE enzymes in mammals, including administering the claimed compounds at specified dosages.
- Pharmaceutical composition claims: Formulated compositions comprising the claimed compounds and excipients suitable for therapeutic use.
- Therapeutic claims: Use of compounds to treat conditions mediated by PDE enzymes, such as pulmonary hypertension, cardiac disorders, or central nervous system disorders.
Claim Structure
- Composition claims are broad, covering subclasses of heterocyclic phosphodiesterase inhibitors.
- Method claims specify administering effective amounts to achieve PDE inhibition.
- Formulation claims focus on specific dosage forms like tablets, capsules, or injectable solutions.
Notable Claim Limitations
- Chemical substituents specific to the heterocyclic core
- Definitions of "effective amount" and specific indications
- Use in mammals, including humans
Patent Landscape Analysis
Patent Family and Related Patents
- The patent is part of a family with counterparts in multiple jurisdictions, including EP, JP, and WO filings.
- Similar patents focus on selective PDE4 inhibitors, indicative of targeting specific PDE subtypes for CNS or respiratory therapies.
Competitor Patent Activity
- Several filings from competitors like GlaxoSmithKline, Novartis, and Merck target PDE inhibitors.
- Patent filings in the mid-1990s to early 2000s primarily focus on PDE4, PDE5, and dual PDE inhibitors.
- The landscape shows intense R&D activity aiming at CNS and respiratory disorders.
Legal Status and Challenges
- The patent remains active with no recent litigations reported.
- There are no known patent interferences or notable legal disputes related directly to this patent.
- Some patents citing this patent suggest ongoing innovation and the importance of the compounds.
Patent Expiry
- Original filing date: 1998
- Expiration date: 20 years from filing, i.e., 2018, unless maintained by payments
- The patent likely expired or is in the process of expiration, opening opportunities for generics or biosimilars.
Citation and Influence
- Cited by over 400 subsequent patents, including those related to PDE inhibitors for cognitive enhancement and respiratory therapies.
- References include improvements in selectivity, bioavailability, and formulation stability.
Implications for the Industry
Therapeutic Area Focus
- PDE inhibitors have broad applications, notably in asthma, COPD, cardiovascular diseases, and CNS disorders.
- This patent's claims underpin several marketed and pipeline drugs targeting these areas.
Innovation Trends
- The patent landscape moved towards selective PDE4 inhibitors for CNS disorders like schizophrenia and depression.
- Combinations of PDE inhibitors with other therapeutic agents became a prominent focus post-2005.
Commercial Impact
- Pfizer’s patent provided market exclusivity for certain PDE inhibitors during its active period.
- Patent expiration diminishes barriers to generic entry in relevant therapeutic classes.
Key Takeaways
- U.S. Patent 6,204,257 claims specific heterocyclic PDE inhibitors and methods for treating PDE-related diseases.
- The patent’s broad claims cover compounds, administration methods, and formulations.
- It forms part of a larger landscape centered on PDE subtype selectivity, with ongoing research expanding the scope.
- The patent expired or is nearing expiry, reducing intellectual property barriers for competitors.
- The patent landscape reveals a focused effort on CNS and respiratory indications, influencing drug development pipelines.
FAQs
1. What chemical classes are covered by the patent?
It covers heterocyclic compounds with specific substituents designed to inhibit PDE enzymes, particularly PDE4.
2. Are there any known challenges or legal issues?
There are no current disputes; the patent is likely expired or close to expiration, with no significant legal challenges reported.
3. How does this patent influence current PDE inhibitor drug development?
It provided foundational claims for PDE inhibitors, influencing subsequent patent filings for drugs with similar mechanisms.
4. Which therapeutic areas are most impacted by this patent?
Respiratory conditions (asthma, COPD), CNS disorders (schizophrenia, depression), and cardiovascular diseases.
5. How does this patent landscape compare to newer PDE inhibitor patents?
Recent patents focus on increased selectivity, reduced side effects, and novel delivery methods, building on the foundational scope of this patent.
References
[1] U.S. Patent 6,204,257. (2001).
[2] Patent family filings, published by Pfizer and related applicants.
[3] Review articles on PDE inhibitors. (PMID: 10026683, 11516811, 17914227)
More… ↓
⤷ Start Trial
|
